<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Chem Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">ACS Chem Neurosci</journal-id><journal-id journal-id-type="publisher-id">cn</journal-id><journal-id journal-id-type="coden">acncdm</journal-id><journal-title-group><journal-title>ACS Chemical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1948-7193</issn><issn pub-type="epub">1948-7193</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25147933</article-id><article-id pub-id-type="pmc">4198061</article-id><article-id pub-id-type="doi">10.1021/cn500126t</article-id><article-categories><subj-group><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Understanding the Role &#x003b1;7 Nicotinic Receptors
Play in Dopamine Efflux in Nucleus Accumbens</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="ath1"><name><surname>Maex</surname><given-names>Reinoud</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Grinevich</surname><given-names>Vladimir
P.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Grinevich</surname><given-names>Valentina</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Budygin</surname><given-names>Evgeny</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff4" ref-type="aff">||</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Bencherif</surname><given-names>Merouane</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Gutkin</surname><given-names>Boris</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Cognitive Sciences, <institution>&#x000c9;cole Normale
Sup&#x000e9;rieure</institution>, Paris 75005, <country>France</country></aff><aff id="aff2"><label>&#x02021;</label><institution>Targacept
Inc.</institution>, Winston-Salem, North Carolina 27101, <country>United States</country></aff><aff id="aff3"><label>&#x000a7;</label><institution>Wake
Forest School of Medicine</institution>, Winston-Salem, North Carolina 27157, <country>United States</country></aff><aff id="aff4"><label>||</label><institution>St. Petersburg
State University</institution>, St. Petersburg 199034, <country>Russia</country></aff><aff id="aff5"><label>&#x022a5;</label>Center
for Cognition and Decision Making, <institution>National
Research University Higher School of Economics</institution>, Moscow 101000, <country>Russia</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>reinoud.maex@ens.fr</email>.</corresp></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>08</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>22</day><month>08</month><year>2014</year></pub-date><pub-date pub-type="collection"><day>15</day><month>10</month><year>2014</year></pub-date><volume>5</volume><issue>10</issue><fpage>1032</fpage><lpage>1040</lpage><history><date date-type="received"><day>06</day><month>06</month><year>2014</year></date><date date-type="accepted"><day>22</day><month>08</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 American Chemical
Society</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American Chemical
Society</copyright-holder></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_0008" id="ab-tgr1"/></p><p>Neuronal nicotinic acetylcholine
receptors (NNRs) of the &#x003b1;7
subtype have been shown to contribute to the release of dopamine in
the nucleus accumbens. The site of action and the underlying mechanism,
however, are unclear. Here we applied a circuit modeling approach,
supported by electrochemical in vivo recordings, to clarify this issue.
Modeling revealed two potential mechanisms for the drop in accumbal
dopamine efflux evoked by the selective &#x003b1;7 partial agonist TC-7020.
TC-7020 could desensitize &#x003b1;7 NNRs located predominantly on dopamine
neurons or glutamatergic afferents to them or, alternatively, activate
&#x003b1;7 NNRs located on the glutamatergic afferents to GABAergic
interneurons in the ventral tegmental area. Only the model based on
desensitization, however, was able to explain the neutralizing effect
of coapplied PNU-120596, a positive allosteric modulator. According
to our results, the most likely sites of action are the preterminal
&#x003b1;7 NNRs controlling glutamate release from cortical afferents
to the nucleus accumbens. These findings offer a rationale for the
further investigation of &#x003b1;7 NNR agonists as therapy for diseases
associated with enhanced mesolimbic dopaminergic tone, such as schizophrenia
and addiction.</p></abstract><kwd-group><kwd>&#x003b1;7-Nicotinic receptor agonist</kwd><kwd>acetylcholine</kwd><kwd>desensitization</kwd><kwd>ventral tegmental area</kwd><kwd>mesolimbic
pathway</kwd><kwd>modeling</kwd></kwd-group><funding-group><funding-statement><funding-source>National Institutes of Health, United States</funding-source></funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>cn500126t</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>cn-2014-00126t</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">Ligands of
neuronal nicotinic
receptors (NNRs) are seen as promising therapeutics for a range of
CNS disorders, including Alzheimer&#x02019;s disease, Parkinson&#x02019;s
disease, schizophrenia, and addiction.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref4">4</xref></sup> NNRs are members of the class of Cys-loop
cationic ion channels, yet predicting the systemic effects of their
ligands has proven difficult for several reasons: NNRs of varying
subunit composition are expressed on different neuron types, locate
extrasynaptically, and quickly desensitize to varying degrees in the
continued presence of the agonist.</p><p>NNRs are abundant in the
basal ganglia,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> and acute systemic nicotine
administration stimulates the efflux
of dopamine in rat nucleus accumbens in vivo.<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> Most
studies on the cholinergic control of accumbal dopamine release have
focused on the effect of activation of different NNR subtypes on the
spiking activity of either dopaminergic<sup><xref ref-type="bibr" rid="ref8">8</xref>&#x02212;<xref ref-type="bibr" rid="ref10">10</xref></sup> or GABAergic neurons<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> in the ventral tegmental area (VTA)<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> or have measured changes in accumbal dopamine levels after electrical
stimulation of midbrain nuclei.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> For short,
&#x003b1;7 NNRs are thought to exert presynaptic control over inputs
to VTA neurons,<sup><xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> and consistent with this modulatory
role, dopamine neurons of &#x003b1;7&#x02013;/&#x02013; mice showed less
prominent changes in their spontaneous or evoked spike patterns than
those of &#x003b2;2&#x02013;/&#x02013; mice.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup></p><p>More recently, optogenetic stimulation of the accumbal cholinergic
interneurons was found to evoke dopamine efflux in vitro without a
concomitant change of the spike rate or pattern of the dopamine neurons.<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref16">16</xref></sup> Although this accumbal control of dopamine efflux is mediated by
preterminal &#x003b2;2* NNRs on the axons of dopamine neurons,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> cholinergic stimulation may also activate nearby
&#x003b1;7 NNRs located on corticofugal axons and, through the intermediary
of ionotropic receptors on dopamine axons, indirectly stimulate dopamine
release.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup></p><p>TC-7020 is a selective partial agonist
of the homomeric &#x003b1;7-type
NNR<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> with an efficacy of 30% and an EC<sub>50</sub> of 30 nM in rats. Its selectivity for the &#x003b1;7 NNR is
evidenced by an IC<sub>50</sub> of 2 nM, compared with 4200 nM for
&#x003b1;4&#x003b2;2* NNRs,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> and an IC<sub>50</sub> &#x0003e; 10 &#x003bc;M for non-nicotinic receptors.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> In a microdialysis study of a mouse model of
schizophrenia,
systemic administration of TC-7020 (0.1&#x02013;1.0 mg/kg ip) normalized
the increased striatal extracellular dopamine level.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The mechanism of action underlying this suppression of
dopamine concentration, however, remains elusive. Since microdialysis
measures dopamine fluctuations only on a time scale of minutes, these
data cannot be effectively used for the computational modeling of
the targeted circuitry. Importantly, &#x003b1;7 NNRs rapidly desensitize
during agonist exposure, and preterminal receptors interact with glutamatergic
transmission in VTA,<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> ventral and dorsal striatum,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> and prefrontal
cortex.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup></p><p>In contrast to microdialysis measurements,
real-time voltammetry
is particularly useful for evaluating the fast dopamine dynamics,
due its subsecond-scale temporal resolution. Here, we used a computational
modeling approach to understand the observation that TC-7020 acutely
reduced dopamine efflux measured by fast-scan cyclic voltammetry (FSCV).
In particular, we examine how real-time dopamine signaling depends
on the activation and desensitization properties of the &#x003b1;7 NNRs
and on their differential distribution on GABA and dopamine neurons
or their glutamatergic afferents. The present analysis models only
acute effects, up to 1 min after agonist injection, since the circuit
may change its dynamics owing to synaptic plasticity<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> or adaptation of the expression of other NNR subtypes.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup></p><sec id="sec2"><title>Results and Discussion</title><p>We first
present the in vivo voltammetric recording of dopamine
efflux in rat nucleus accumbens in response to the iv injection of
nicotine and the partial &#x003b1;7 agonist TC-7020. Next we explain
how two alternative models, based on desensitization versus activation
of the &#x003b1;7 receptor, generated a drop in dopamine release similar
to that after TC-7020 injection. Finally, we argue that only one particular
implementation of the desensitization model explains the observed
response to the combined injection of the positive allosteric modulator
PNU-120596.</p><sec id="sec2.1"><title>In Vivo Voltammetry of Dopamine Efflux in Rat Nucleus Accumbens</title><p>Intravenous administration of nicotine (0.3 mg/kg) induced a fast
and potent increase in accumbal dopamine measured by real-time FSCV
in anesthetized rats (Figure <xref rid="fig1" ref-type="fig">1</xref>A). The averaged
dopamine concentration was 0.82 &#x000b1; 0.08 &#x003bc;M (<italic>n</italic> = 4). The effect appeared approximately 7 s after drug administration.
Importantly, an identical nicotine-induced dopamine concentration
increase had been observed in freely moving rats using the same technique
(FSCV).<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> No changes were observed after
saline injection (Figure <xref rid="fig1" ref-type="fig">1</xref>A,B). Using the same
experimental design, we explored the effects of the &#x003b1;7-selective
partial agonist TC-7020 (1 mg/kg iv) on real-time dopamine dynamics
(Figure <xref rid="fig1" ref-type="fig">1</xref>B,C). In contrast to nicotine, this
compound induced a drop in baseline dopamine recordings. This inhibitory
effect could be reversed by nicotine (Figure <xref rid="fig1" ref-type="fig">1</xref>B). The TC-7020-induced drop was nearly abolished by pretreatment
with MLA (10 mg/kg ip), an &#x003b1;7 nicotinic receptor antagonist
(Figure <xref rid="fig1" ref-type="fig">1</xref>C), ruling out the possibility that
the observed dopamine changes were nonspecific or nonreceptor mediated.
No changes were observed when MLA was administered alone (Figure <xref rid="fig1" ref-type="fig">1</xref>C). A previous microdialysis study also had provided
clear evidence that systemic (ip) administration of TC-7020 could
suppress extracellular dopamine levels on a prolonged time scale.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Interestingly, in the present experiments, pretreatment
with the &#x003b1;7 type-2 positive allosteric modulator PNU-120596
(5 mg/kg, sc),<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> rather than enhancing
dopamine release, also blocked the effects of TC-7020 on dopamine
transmission, through an expected reduction or elimination of desensitization
(see Figure <xref rid="fig4" ref-type="fig">4</xref>A). Qualitatively similar observations
were made in the dorsal striatum.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Representative voltammetric recordings
of real-time dopamine signaling
in nucleus accumbens of anaesthetized rats before and after administration
(arrows) of (A) nicotine (0.3 mg/kg iv), (B) TC-7020 (1 mg/kg iv)
followed by nicotine, and (C) TC-7020 alone (blue trace) or TC-7020
after pretreatment with MLA (10 mg/kg ip) (green trace) or MLA alone
(black trace). Black traces in A and B are controls after saline injection.
Inset to panel A is representative background-subtracted voltammogram
obtained at peak of response, showing characteristic oxidation and
reduction peak potentials (approximately +0.6 V and approximately
&#x02212;0.2 V, respectively) that identify dopamine.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_0002" id="gr1" position="float"/></fig></sec><sec id="sec2.2"><title>Analysis of the Drop in Dopamine Release
Produced in Models
Based on the Desensitization versus Activation of &#x003b1;7 NNRs</title><p>In order to explain these observations, we compared two classes
of models based either on the activation or on the desensitization
of &#x003b1;7 NNRs. The models differed by the relative distribution
of &#x003b1;7 NNRs on dopamine versus GABA-neurons (or their glutamatergic
afferents), and as will be shown below, they functioned optimally
at different TC-7020 concentrations and different cholinergic tones.</p><p>In the first class of models, NNRs were primarily expressed on
dopamine neurons and glutamatergic fibers afferent to them (Figure <xref rid="fig2" ref-type="fig">2</xref>A). The channels were located, first, within the
VTA on the glutamatergic afferents to dopamine neurons, where they
potentiate glutamate release;<sup><xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup> second, on the dendrites and somata of (a subpopulation of) dopamine
neurons;<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref31">31</xref>&#x02212;<xref ref-type="bibr" rid="ref33">33</xref></sup> and, third, within the
nucleus accumbens, on the glutamatergic afferents to the medium-sized
spiny neurons, where they potentiate glutamate release and subsequent
dopamine release through a process involving ionotropic glutamate
receptors presumably located on the dopamine axons.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup> The &#x003b1;7 NNRs are notably absent, however, from the dopamine
axonal terminals themselves.<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> Since desensitization
of receptors at these locations would indeed reduce dopamine release,
we further call this class of models the &#x0201c;desensitization model&#x0201d;.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Synaptic
organization and responses of the &#x0201c;desensitization
model&#x0201d;. Panel A shows a circuit diagram of the mesoaccumbal
projection, highlighting the locations of those &#x003b1;7 NNRs that
would evoke, through their desensitization, a drop in dopamine release.
Panel B plots the extracellular dopamine dynamics in the model for
four levels of cholinergic tone, indicated by their equivalent acetylcholine
concentrations. The [TC-7020] profile is shown in Figure S2, <xref rid="notes-2" ref-type="notes">Supporting Information</xref>, and TC-7020 reached a
peak concentration of 11 nM. MSN, medium-sized spiny neuron; glu,
glutamatergic afferent. For clarity, the &#x003b1;4&#x003b2;2* NNRs on
the DA and GABA neurons or their afferents are not shown.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_0003" id="gr2" position="float"/></fig><p>In contrast, when the &#x003b1;7 NNRs were located
primarily at the
positions highlighted in Figure <xref rid="fig3" ref-type="fig">3</xref>A, they would
evoke a drop in dopamine efflux through receptor activation, and this
class of models is further referred to as the &#x0201c;activation model&#x0201d;.
Its channels can be located on glutamatergic afferents to GABA neurons
in the VTA (but no &#x003b1;7 NNRs are located on the GABA neurons themselves),<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and their activation disynaptically inhibits
dopamine neurons. Alternatively, activation of &#x003b1;7 NNRs on glutamate
afferents within the nucleus accumbens can, through spillover of glutamate,
activate metabotropic glutamate receptors on dopamine terminals and
depress dopamine release.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup></p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Synaptic organization
and responses of the &#x0201c;activation model&#x0201d;.
The &#x003b1;7 NNRs located at the positions in panel A would evoke,
through their activation, a drop in dopamine release. Panel B plots
the extracellular dopamine dynamics in the model for three levels
of cholinergic tone, indicated by their equivalent acetylcholine concentrations.
The [TC-7020] profile is shown in Figure S2, <xref rid="notes-2" ref-type="notes">Supporting
Information</xref>, and TC-7020 reached a peak concentration of 3
nM.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_0004" id="gr3" position="float"/></fig><p>The simulations showed that both
models could reproduce the TC-7020-evoked
drop in dopamine release (Figures <xref rid="fig2" ref-type="fig">2</xref>B and <xref rid="fig3" ref-type="fig">3</xref>B). The responses of the desensitization model,
however, depended on the cholinergic tone, which was represented in
the model by an equivalent concentration of acetylcholine needed to
obtain a tonic level of receptor activation. At absent tone ([ACh]
= 0 in Figure <xref rid="fig2" ref-type="fig">2</xref>B), the net response was an
enhanced dopamine efflux, caused by activation and subsequent (incomplete)
desensitization of the &#x003b1;7 NNRs. In the presence of a tone, however,
the desensitization would reduce the numbers of NNRs available for
endogenous acetylcholine, leading to a marked drop in the level of
dopamine efflux, in proportion to the strength of the tone (Figure <xref rid="fig2" ref-type="fig">2</xref>B).</p><p>In contrast, no cholinergic tone was required
in the activation
model (Figure <xref rid="fig3" ref-type="fig">3</xref>B). A high tone even reversed
the dopamine drop since desensitization of NNRs now disinhibited the
dopamine neuron (red curve in Figure <xref rid="fig3" ref-type="fig">3</xref>B). For
the activation model to cause a sustained drop in dopamine efflux,
however, a &#x0201c;window&#x0201d; current was needed, which required
agonist levels at concentrations where the desensitization and activation
curves maximally overlapped (see Figure <xref rid="fig5" ref-type="fig">5</xref>).
The desensitization model, on the other hand, required higher agonist
concentrations that would desensitize most of the NNRs. A more extensive
parameter analysis of the model can be found in the <xref rid="notes-2" ref-type="notes">Supporting Information</xref> (Figures S2&#x02013;4).</p></sec><sec id="sec2.3"><title>The Activation
and Desensitization Models Make Opposite Predictions
Regarding the Effect of a Coadministered Positive Modulator</title><p>As mentioned above, coadministration of PNU-120596, a type-2 positive
allosteric modulator of &#x003b1;7 NNRs that releases the receptors
from desensitization,<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> abolished the TC-7020
response (Figure <xref rid="fig4" ref-type="fig">4</xref>A). We modeled NNR resensitization by shifting the Hill curve of
the desensitization gate of the receptors toward higher agonist concentrations.
In that case, the desensitization model robustly reproduced the experimental
cancellation of the TC-7020-induced drop in dopamine release (Figure <xref rid="fig4" ref-type="fig">4</xref>B and Figure S4, <xref rid="notes-2" ref-type="notes">Supporting
Information</xref>).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Responses to coadministration of TC-7020 and PNU-120596
in the
experiment (A) and model (desensitization, B, and activation, C).
Doses and parameters were as follows: (A) TC-7020 (1.0 mg/kg iv) and
PNU-120596 (5.0 mg/kg injected sc 30 min earlier); (B) peak [TC-7020]
11 nM, ACh tone 30 &#x003bc;M; (C) peak [TC-7020] 2.4 nM, ACh tone 0
&#x003bc;M. The presence of PNU-120596 was modeled by multiplying the
IC<sub>50</sub> of TC-7020 by a factor of 10.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_0005" id="gr4" position="float"/></fig><p>In the activation model, in contrast, shifting rightward
the desensitization
curves always amplified the TC-7020 response, instead of neutralizing
it (Figure <xref rid="fig4" ref-type="fig">4</xref>C). For the TC-7020 response to
be canceled in the activation model, PNU-120596 should be assumed
to interfere with receptor activation. Although prolonged channel
opening in the presence of PNU-120596 can make the channels more susceptible
to open-channel-block, this phenomenon has been observed only at much
higher, micromolar agonist concentrations.<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup></p></sec><sec id="sec2.4"><title>The Combined Voltammetry-Modeling Results Point to a Desensitizing
Action of TC-7020 on &#x003b1;7 NNRs Located on Glutamatergic Afferents
in Nucleus Accumbens</title><p>In summary, the present model considered
five different sites for the action of TC-7020 on the mesoaccumbal
pathway, and hence for the contribution of &#x003b1;7 NNRs to dopamine
release. Although models based on NNR desensitization (sites 1&#x02013;3
in Figure <xref rid="fig2" ref-type="fig">2</xref>A) and NNR activation (sites 4 and
5 in Figure <xref rid="fig3" ref-type="fig">3</xref>A) could both generate a drop
in dopamine release such as that observed experimentally, the neutralizing
effect of coadministered PNU-120596 was only explained by the desensitization
model (receptor resensitization by the allosteric modulator, sites
1&#x02013;3). Sites 4 and 5 of the activation model further lack experimental
support. For site 5, although stimulation of presynaptic metabotropic
glutamate receptors (mGluR1) has been shown to reduce dopamine release
in mouse striatum in vitro,<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> mGluR1 agonists
were ineffective in dialysis experiments.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> In addition, although local application of the partial &#x003b1;7
agonist JN403 at site 4 has been observed to enhance the spike rate
of GABAergic neurons via action on &#x003b1;7 NNRs at glutamatergic
terminals<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and optogenetic stimulation
of GABA neurons reduced dopamine efflux in nucleus accumbens,<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> systemic administration of &#x003b1;7 agonists
did not affect the rate or spike pattern of dopamine neurons (Figure
7 of ref (<xref ref-type="bibr" rid="ref41">41</xref>)).</p><p>This failure of systemically applied &#x003b1;7 agonists to acutely
alter the spiking behavior of dopamine neurons also disfavors sites
1 and 2 of the desensitization model (Figure <xref rid="fig2" ref-type="fig">2</xref>A), leaving site 3 as the most likely mesoaccumbal target for TC-7020.
Such a contribution of accumbal &#x003b1;7 NNRs to dopamine release
was first proposed by Kaiser and Wonnacott.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Note that TC-7020 itself does not evoke dopamine release from synaptosomes
(V. P. Grinevich and M. Bencherif, unpublished data); hence the mechanism
involves crosstalk among cholinergic, glutamatergic, and dopaminergic
neurons. That cortico-accumbal glutamatergic neurons could facilitate
dopamine release through a presynaptic action on the dopamine terminals,
independently of the rate of firing of meso-accumbal dopamine neurons,
had been suggested before,<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> and subsequent
studies confirmed the presence of ionotropic glutamate receptors on
dopaminergic synaptosomes<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> and of &#x003b1;7 NNRs
on glutamatergic terminals.<sup><xref ref-type="bibr" rid="ref44">44</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> Electrochemical recordings
in nucleus accumbens and VTA of freely moving rats showed that low
doses of nicotine (30 &#x003bc;g/kg iv) acutely stimulated glutamate
efflux.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> In the VTA, at least, nicotine-evoked
glutamate efflux has been suggested to be mediated through &#x003b1;7
receptors.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup></p><p>As shown by the model,
the effect of &#x003b1;7 NNR desensitization
on dopamine release can only be apparent in the presence of a cholinergic
tone. In nucleus accumbens, acetylcholine is released by giant interneurons
that fire spontaneously at a rate of 3&#x02013;10 Hz in vivo.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> The presence of a cholinergic tone activating
preterminal &#x003b1;7 NNRs in vitro was demonstrated by the drop of
excitatory post-synaptic current (EPSC) frequency in medium-sized
spiny neurons after bath application of MLA.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> Taken together, these data indicate that &#x003b1;7 NNRs contribute
to the cholinergic control of dopamine release in nucleus accumbens,
even at baseline receptor recruitment levels, and hence that their
acute desensitization indeed will reduce dopamine efflux.</p><p>Note
that this mechanism has been suggested before, for instance,
to underlie the drop in dopamine after intrastriatal infusion of kynurenic
acid, which can act as an &#x003b1;7 inhibitor,<sup><xref ref-type="bibr" rid="ref49">49</xref>&#x02212;<xref ref-type="bibr" rid="ref51">51</xref></sup> and for the
regularization of enhanced dopamine release in a mouse model of schizophrenia.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The loss of regulatory action of &#x003b1;7 NNRs
has likewise been suggested to underlie to enhanced nicotine-evoked
dopamine release in the accumbens of &#x003b1;7&#x02013;/&#x02013; mutant
mice.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup></p><p>Last but not least we have
to discard the possibility that TC-7020
did not act by reducing dopamine efflux but by stimulating its reuptake.
In the model, a 15% increase of transport velocity would have sufficed
to generate a drop in dopamine concentration of the same magnitude
as that generated by receptor desensitization. However, in a previous
study,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> 10 &#x003bc;M TC-7020 did not show
any affinity for the dopamine transporter in a radioligand assay.
Neither glutamate<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> nor nicotine<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> interacts with the dopamine uptake transporter.
Moreover, such an interaction of TC-7020 with the dopamine transporter
would not have explained the effects evoked by MLA (Figure <xref rid="fig1" ref-type="fig">1</xref>C) and PNU-120596 (Figure <xref rid="fig4" ref-type="fig">4</xref>A).</p></sec><sec id="sec2.5"><title>Robustness of the Model</title><p>Predicting the systemic effects
of a partial agonist requires knowledge of the balance between receptor
activation and desensitization and further of the distribution of
the receptors at different locations within the circuit.</p><p>For
the receptor, steady-state can be assumed, since &#x003b1;7 NNRs desensitize
on a subsecond time scale. In that case the fraction of conducting
receptors is described by the product of the concentration&#x02013;response
curves for activation and desensitization (Figure <xref rid="fig5" ref-type="fig">5</xref>A). The resultant window
current has a bell-shaped concentration profile (Figure <xref rid="fig5" ref-type="fig">5</xref>B, curve [ACh] = 0), and its amplitude increases with the
efficacy of the compound (Figure <xref rid="fig5" ref-type="fig">5</xref>C). From
the current gained by binding of the exogenous agonist, however, the
loss of endogenous current that is due to desensitization must be
subtracted. This loss increases with cholinergic tone. The net current
diminishes and its peak shifts toward lower agonist concentrations,
until at high tone the agonist produces at all concentrations a negative
effect (Figures <xref rid="fig5" ref-type="fig">5</xref>B,C).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Effect of TC-7020 on
acetylcholine-evoked dopamine release summarized.
(A) Steady-state activation and desensitization curves for TC-7020
at &#x003b1;7 NNRs. The black arrow indicates the concentration at which
TC-7020 is maximally able to activate NNRs without completely desensitizing
them. Beyond this concentration, the desensitizing effect on endogeneous
release (&#x0201c;ACh tone&#x0201d;) predominates (gray arrow). (B)
Each trace plots the difference between the NNR current that is generated
by the combined presence of TC-7020 and acetylcholine and the NNR
current generated by acetylcholine alone. TC-7020 concentration is
plotted on the horizontal axis; ACh tone is color-coded. (C) Same
data as in panel B, but for a full agonist.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_0006" id="gr5" position="float"/></fig><p>As stated above, the desensitization and activation mechanisms
operate in different concentration regimes, the latter being able
to generate a current only at lower ligand concentrations at which
a considerable fraction of NNRs did not desensitize yet (black arrow
in Figure <xref rid="fig5" ref-type="fig">5</xref>A). Nevertheless in both regimes
most of the receptors will desensitize, except when the concentration&#x02013;response
curves for desensitization and activation considerably overlap.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> A third mechanism, receptor potentiation, can
be considered as a special case of the activation mechanism, operating
at agonist concentrations too low to desensitize the receptor but
sufficient to open the channel through coagonism with acetylcholine.
Although we cannot exclude that this mechanism may be viable within
a limited range of concentrations of agonist and acetylcholine (see
Supplementary Modeling Results in <xref rid="notes-2" ref-type="notes">Supporting Information</xref>), it would be incompatible with the effect of coadministered PNU-120596.</p><p>The same principles hold for the nicotine response, which was evoked
in the model by the activation, and subsequent desensitization, of
&#x003b1;4&#x003b2;2 NNRs. Following Figure <xref rid="fig5" ref-type="fig">5</xref>C,
such a positive response is easier to obtain when the activation and
desensitization curves substantially overlap (see Figure S1C, <xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and when the efficacy
is high and cholinergic tone low.</p><p>The second determinant of
the response, the relative expression
of functional &#x003b1;7 receptors by different neuron types, is difficult
to quantify. Although transcription can be measured,<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> most receptors are located intracellularly, and electron microcopy
is needed to confirm their subcellular position at the plasma membrane.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> In addition, electrophysiological responses
after local versus systemic application may differ.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> Given that insufficient information is available about
the actual distribution of &#x003b1;7 NNRs, we simulated two rather
extreme cases with 80% of &#x003b1;7 NNRs located on dopamine neurons
or their afferents (the desensitization model, <italic>s</italic> =
0.8) and all of them on the afferents to GABA neurons (the activation
model, <italic>s</italic> = 0). Apart from these two cases, the responses
from intermediate distributions can be derived as follows. Given that
the strength of inhibition from GABA neurons to dopamine neurons in
the VTA had a relative weight of 1.5, all &#x003b1;7 responses would
virtually disappear in dopamine neurons at a distribution factor <italic>s</italic> of 0.6 (40% of &#x003b1;7 NNRs on afferents to GABA neurons)
since currents of similar amplitude but opposite sign would cancel
each other. At still lower values of <italic>s</italic>, the responses
of the dopamine neuron would change sign, and be mirror symmetric
about the baseline with respect to those shown before for the desensitization
model. (The same reasoning can be applied to the responses of the
activation model, with a reduction of response amplitude as <italic>s</italic> starts rising from 0 and a sign reversal at <italic>s</italic> = 0.6.)</p><p>Similar mechanisms of dopamine modulation can take
place in other
brain regions, for example, in the dorsal striatum. However, since
the innervations of the striatum and nucleus accumbens are divergent,
some distinction can be expected. In the <xref rid="notes-2" ref-type="notes">Supporting
Information</xref>, we discuss how the same principles may apply to
predict &#x003b1;7-evoked dopamine release in prefrontal cortex.</p></sec><sec id="sec2.6"><title>Limitations
of the Present Study</title><p>A final note is needed
on the calibration of the two model variables representing the cholinergic
and dopaminergic tones, respectively. The cholinergic tone was modeled
by a parameter giving the equivalent concentration needed for endogenous
acetylcholine to generate a certain steady-state level of receptor
activation. Even though many NNRs are located extrasynaptically, the
equivalent concentration should not be interpreted as the concentration
of acetylcholine in extracellular space, which is in the low nanomolar
range.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> At best it could represent the
acetylcholine concentration close to the synaptic release site, given
that the fast &#x003b1;7 NNR responses are presumably generated, at
least in neocortex, by classical synaptic transmission.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup></p><p>As for the extracellular dopamine concentration,
baseline estimates from voltammetry vary from 20&#x02013;30 nM<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> to 73 nM<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> to 95&#x02013;220
nM.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> Extracellular dopamine concentration
may also be spatially heterogeneous, with some patches having concentrations
in the low micromolar range.<sup><xref ref-type="bibr" rid="ref51">51</xref>,<xref ref-type="bibr" rid="ref61">61</xref></sup> In the present FSCV
measurements (Figure <xref rid="fig1" ref-type="fig">1</xref>), no information about
quantitative basal dopamine levels was obtained because all data were
background subtracted. Drops below baseline have been recorded before,<sup><xref ref-type="bibr" rid="ref51">51</xref>,<xref ref-type="bibr" rid="ref59">59</xref></sup> but their magnitude is difficult to quantify, because no dopamine
cyclic voltammogram (inset to Figure <xref rid="fig1" ref-type="fig">1</xref>A) can
be obtained when the baseline goes down, and small artifacts can be
involved in the drop (such as pH changes). Neither can the present
model decide on the amplitude of baseline or evoked dopamine responses.
The model assumed a baseline dopamine concentration of 50 nM, but
some other parameters (including the brain profile of TC-7020 concentration
and nicotine concentration after fast iv injection) are poorly constrained.
Figure <xref rid="fig6" ref-type="fig">6</xref> shows how similar realistic dopamine
responses can be obtained with a slower clearance of TC-7020 and nicotine
and with a baseline dopamine concentration of 337 nM.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Simulated accumbal dopamine
response to TC-7020 and nicotine starting
from a baseline [dopamine] of 337 nM. The compounds were administered
with a &#x003c4;<sub>in</sub> of 10 s and &#x003c4;<sub>out</sub> of 200
s. Simulations of the desensitization model with its standard parameters,
except for a weaker connection weight from the GABAergic to dopaminergic
neurons (1 vs 1.5) and a different cholinergic tone at &#x003b1;7 versus
&#x003b1;4&#x003b2;2 NNRs (33 vs 3 &#x003bc;M). The red trace plots the
response after pretreatment with PNU-120596.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_0007" id="gr6" position="float"/></fig></sec></sec><sec sec-type="conclusions" id="sec3"><title>Conclusion</title><p>The present study is compatible with a mechanism
of glutamatergic
control of dopamine efflux in nucleus accumbens, in which neither
glutamate nor dopamine requires spikes to be released.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Acetylcholine binding to &#x003b1;7 receptors
on glutamatergic terminals promotes the spillover of glutamate to
dopaminergic terminals, where binding to ionotropic receptors leads
in turn to dopamine release.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Our combined
experimental and modeling results indicate that partial agonists such
as TC-7020 may suppress dopamine release by desensitizing the &#x003b1;7
receptors.</p></sec><sec sec-type="methods" id="sec4"><title>Methods</title><sec sec-type="methods" id="sec4.1"><title>Experimental Procedure</title><p>Male Sprague&#x02013;Dawley rats
(Charles Rivers Laboratories, Raleigh, NC) weighing 300&#x02013;400
g, which were housed two animals per cage with ad libitum food and
water in a 12/12 h light/dark cycle, were used in our in vivo voltammetric
studies. All procedures were approved by the Wake Forest University
and University of North Carolina Animal Care and Use Committees. Experiments
were performed on anesthetized animals.</p><p>At the day of experiment,
naive rats were surgically implanted with indwelling iv catheters
under urethane (1.5 g/kg ip) anesthesia using aseptic procedures immediately
before voltammetric assessments. A tapered polyurethane catheter was
implanted into the right external jugular vein with the catheter exiting
the skin behind the ear. A muscle tie served as a tether, preventing
the catheter from being dislodged during subsequent voltammetric assessments.
Following surgery, the implanted catheter was flushed with 0.2&#x02013;0.3
mL of sterile 0.9% saline, and the catheter was clamped until later
use during the voltammetric experiment. Then rats were head-restrained
in a stereotaxic frame, and a carbon fiber electrode (50&#x02013;100
&#x003bc;m exposed tip length, 7 &#x003bc;m diameter; Goodfellow, Oakdale,
PA, USA) was positioned in the nucleus accumbens core (AP + 1.3, L
+ 1.3, V &#x02013; 6.7&#x02013;7.0 mm from bregma) with a Ag/AgCl reference
electrode implanted in the contralateral hemisphere. The reference
and carbon fiber electrodes were connected to a head-mounted voltammetric
amplifier (UNC Electronics Design Facility, Chapel Hill, NC) and voltammetric
recordings were made at the carbon fiber electrode every 100 ms by
applying a triangular waveform (&#x02212;0.4 to +1.3 V, 300 V/s). Data
were digitized (National Instruments, Austin, TX) and stored on a
computer. To confirm the placement of electrodes, a 200 &#x003bc;A current
was passed through a stainless steel electrode for 10 s. Brain was
removed and postfixed in 10% formalin for at least 3 days. After freezing,
50 &#x003bc;m coronal brain sections were taken and mounted throughout
the rostral-caudal extent of the nucleus accumbens. The position of
electrodes was assessed by visual examination of coronal sections
for electrolytic lesions.</p><p>Nicotine (0.3 mg/kg), TC-7020 phosphate
(1.0 mg/kg), and saline
were administered intravenously as an experimenter-delivered bolus
over 4&#x02013;6 s in a volume of 0.3&#x02013;0.4 mL. Methyllycaconitine
citrate (MLA, 10 mg/kg) and the &#x003b1;7-selective type-2 positive
allosteric modulator PNU-120596 (5.0 mg/kg) were injected intraperitoneally
(ip) and subcutaneously (sc), respectively, 30 min before TC-7020
administration.<sup><xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref></sup> The effect of every compound
on dopamine dynamics was replicated on four animals. These results
were used for the modeling procedure. TC-7020 was provided by Targacept,
Inc., PNU-120596 was purchased from Sigma-Aldrich (St. Louis, MO),
and MLA was purchased from Tocris Bioscience (Bristol, U.K.).</p></sec><sec id="sec4.2"><title>Modeling
Methods</title><p>The mathematical model represented
the mesoaccumbens pathway and incorporated both receptor kinetics
and network dynamics. Program code was written in XPP.</p><sec id="sec4.2.1"><title>Receptor
Model</title><p>Each NNR subtype had an activation and
a desensitization gate, resulting in four possible receptor states,
with the fraction of conducting receptors being the product of those
being active, <italic>a</italic>, and sensitive, <italic>s</italic>.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> The steady-state concentration&#x02013;response
curves, <italic>a</italic><sub>&#x0221e;</sub> and (1 &#x02013; <italic>s</italic><sub>&#x0221e;</sub>) for each gate were described as Hill
functions (Figure S1, <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). More particularly, steady-state activation, <italic>a</italic><sub>&#x0221e;</sub>, was calculated as<disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_m001" position="anchor"/></disp-formula>where <italic>x</italic><sub><italic>i</italic></sub> is the concentration of the <italic>i</italic>th agonist, <italic>K</italic><sub><italic>i</italic></sub> is the agonist&#x02019;s EC<sub>50</sub> value (half-maximally effective
concentration), and <italic>n</italic><sub><italic>i</italic></sub> is its Hill-exponent (<italic>n</italic><sub>Ha</sub> in Table <xref rid="tbl1" ref-type="other">1</xref>). In this sum, the fraction represents the fractional
occupancy of the receptor by agonist <italic>i</italic>, which is
multiplied by the agonists&#x02019;s efficacy <italic>w</italic><sub><italic>i</italic></sub>. For <italic>w</italic><sub><italic>i</italic></sub>, the <italic>E</italic><sub>max</sub> values from Table <xref rid="tbl1" ref-type="other">1</xref> were used.</p><p>The degree of desensitization
(1 &#x02013; <italic>s</italic><sub>&#x0221e;</sub>) was calculated
using the same formula, substituting the values of DC<sub>50</sub> and <italic>n</italic><sub>Hs</sub> for <italic>K</italic><sub><italic>i</italic></sub> and <italic>n</italic><sub><italic>i</italic></sub>. Because nicotine and TC-7020 desensitized the receptor completely
at high concentrations (see Figure S1A,B, <xref rid="notes-2" ref-type="notes">Supporting
Information</xref>), their weight factor <italic>w</italic><sub><italic>i</italic></sub> was unity. The <italic>w</italic><sub><italic>i</italic></sub> of endogenous acetylcholine at the desensitization gate, on
the other hand, was set to zero (no desensitization at all) to reflect
in vivo the physiological conditions where the transmitter is rapidly
hydrolyzed by acetylcholine esterase before desensitization can start.</p><p>The acetylcholine parameter in the present model determined the
degree of endogenous cholinergic activity, or cholinergic tone, which
was assumed to be constant during the course of a recording. The release
of acetylcholine not being modeled explicitly, the average tone that
it generated was represented by an equivalent concentration constant,
[ACh], which was set so as to generate an average level of receptor
activation, relative to which the applied exogenous compounds exerted
their action either through further activation, deactivation (competition),
or desensitization.</p><p>Finally, activation was always fast (time
constant 5 ms), whereas
the time constant of desensitization varied between minimum and maximum
values in a concentration-dependent manner according to the same Hill
function as its steady-state<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> (from 120
s to 50 ms for &#x003b1;7 NNRs; from 600 s to 500 ms for &#x003b1;4&#x003b2;2
NNRs).</p><p>Figure S1, <xref rid="notes-2" ref-type="notes">Supporting Information</xref>, shows
the steady-state activation and desensitization curves used in the
model for TC-7020 (panel A) and nicotine (panel B) at the &#x003b1;7
NNRs and for nicotine at the &#x003b1;4&#x003b2;2* NNRs (panel C). The
time traces above each pair of concentration&#x02013;response curves
plot the mean channel current at varying agonist concentrations, illustrating
the concentration dependency of the speed of desensitization and the
faster desensitization of &#x003b1;7 compared with &#x003b1;4&#x003b2;2*
NNRs. Table <xref rid="tbl1" ref-type="other">1</xref> lists the parameters of the Hill
functions, which took the same values as in Graupner et al.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> except where a new reference is given. Most
of these parameters had been taken from Fenster et al.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> and Buisson and Bertrand.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup></p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Parameters of the Hill Functions Used
to Model the Receptors&#x02019; Activation and Desensitization Gates</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x003b1;7</th><th style="border:none;" align="center">TC-7020</th><th style="border:none;" align="center">nicotine</th><th style="border:none;" align="center">acetylcholine</th></tr></thead><tbody><tr><td style="border:none;" align="left">EC<sub>50</sub><xref rid="t1fn1" ref-type="table-fn">a</xref> (&#x003bc;M)</td><td style="border:none;" align="left">0.03</td><td style="border:none;" align="left">13<xref rid="t1fn4" ref-type="table-fn">d</xref></td><td style="border:none;" align="left">68<xref rid="t1fn4" ref-type="table-fn">d</xref></td></tr><tr><td style="border:none;" align="left"><italic>n</italic><sub>Ha</sub><xref rid="t1fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">1.73</td><td style="border:none;" align="left">1.73</td><td style="border:none;" align="left">1.73</td></tr><tr><td style="border:none;" align="left">DC<sub>50</sub><xref rid="t1fn1" ref-type="table-fn">a</xref> (&#x003bc;M)</td><td style="border:none;" align="left">0.002</td><td style="border:none;" align="left">1.3</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><italic>n</italic><sub>Hs</sub><xref rid="t1fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">2</td><td style="border:none;" align="left">2</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><italic>E</italic><sub>max</sub><xref rid="t1fn3" ref-type="table-fn">c</xref> (%)</td><td style="border:none;" align="left">30</td><td style="border:none;" align="left">80</td><td style="border:none;" align="left">100</td></tr></tbody></table><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x003b1;4&#x003b2;2</th><th style="border:none;" align="center">TC-7020</th><th style="border:none;" align="center">nicotine</th><th style="border:none;" align="center">acetylcholine</th></tr></thead><tbody><tr><td style="border:none;" align="left">EC<sub>50</sub><xref rid="t1fn1" ref-type="table-fn">a</xref> (&#x003bc;M)</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">0.23<xref rid="t1fn5" ref-type="table-fn">e</xref></td><td style="border:none;" align="left">30</td></tr><tr><td style="border:none;" align="left"><italic>n</italic><sub>Ha</sub><xref rid="t1fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">1.05</td><td style="border:none;" align="left">1.05</td></tr><tr><td style="border:none;" align="left">DC<sub>50</sub><xref rid="t1fn1" ref-type="table-fn">a</xref> (&#x003bc;M)</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">0.061</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><italic>n</italic><sub>Hs</sub><xref rid="t1fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">0.5</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><italic>E</italic><sub>max</sub><xref rid="t1fn3" ref-type="table-fn">c</xref> (%)</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">80<xref rid="t1fn6" ref-type="table-fn">f</xref></td><td style="border:none;" align="left">100</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>EC<sub>50</sub> (DC<sub>50</sub>), concentration of half-maximal activation (desensitization).</p></fn><fn id="t1fn2"><label>b</label><p><italic>n</italic><sub>Ha</sub> (<italic>n</italic><sub>Hs</sub>), Hill exponent of activation (desensitization).</p></fn><fn id="t1fn3"><label>c</label><p><italic>E</italic><sub>max</sub>, efficacy.</p></fn><fn id="t1fn4"><label>d</label><p>See ref (<xref ref-type="bibr" rid="ref72">72</xref>).</p></fn><fn id="t1fn5"><label>e</label><p>See ref (<xref ref-type="bibr" rid="ref68">68</xref>).</p></fn><fn id="t1fn6"><label>f</label><p>See ref (<xref ref-type="bibr" rid="ref73">73</xref>).</p></fn></table-wrap-foot></table-wrap><p>Model parameters for the &#x003b1;4&#x003b2;2* NNR were
identical to
those used by Graupner et al.,<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> except
for the lower efficacy (0.8) and a higher affinity (EC<sub>50</sub> 230 nM) of nicotine, such as is typical of &#x003b1;6-containing &#x003b1;4&#x003b2;2
NNRs.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup></p><p>The last column of Table <xref rid="tbl1" ref-type="other">1</xref> also implies
that the model&#x02019;s endogenous transmitter, acetylcholine (ACh),
activated the receptors without desensitizing them. As stated above,
this feature reflects the fundamental difference in kinetics between
physiologically released acetylcholine, which is rapidly broken down
by ACh-esterase, and exogenous compounds such as nicotine and TC-7020.</p></sec><sec id="sec4.2.2"><title>Circuit Model</title><p>The circuit represented a population
of dopaminergic neurons that received inhibition from a local population
of GABAergic interneurons.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> The output
variables of the model were the mean-field average population activities
and the resulting extracellular dopamine concentration. Each population
(or its glutamatergic afferents) expressed NNRs of the &#x003b1;7 and
&#x003b1;4&#x003b2;2* subtypes.</p><p>The relative expression of each
subtype across the dopamine and GABA neurons was determined by two
parameters, <italic>r</italic> (for &#x003b1;4&#x003b2;2) and <italic>s</italic> (for &#x003b1;7). A parameter value of 1 indicated that
the corresponding NNR subtype was expressed exclusively by the dopamine
neuron population (or its glutamatergic afferents); a value of 0.5
meant a balanced distribution across the two neuron populations.</p><p>The value of <italic>s</italic> was the major parameter distinguishing
the so-called desensitization and activation models. It determined
the relative expression of &#x003b1;7 NNRs on the two neuron populations
or their afferents: 80% of &#x003b1;7 NNRs were located on the dopamine
neuron or its afferents in the desensitization model (<italic>s</italic> = 0.8) versus all &#x003b1;7 NNRs on the GABA neuron&#x02019;s afferents
in the activation model (<italic>s</italic> = 0). The principal locations
of &#x003b1;7 NNRs compatible with these two models are as depicted
in the respective circuit diagrams of Figures <xref rid="fig2" ref-type="fig">2</xref>A and <xref rid="fig3" ref-type="fig">3</xref>A. Most &#x003b1;4&#x003b2;2* NNRs were
located on the dopamine neuron in both versions of the model: <italic>r</italic> = 0.8 (0.7) for desensitization (activation) model.</p><p>Evidently, the NNRs at the locations depicted in Figures <xref rid="fig2" ref-type="fig">2</xref>A and <xref rid="fig3" ref-type="fig">3</xref>A act all in concert,
but for the sake of clarity, we accentuated their relative contributions
in the model. A final difference with the circuit model of Graupner
et al.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> concerned the connection strength
from GABAergic onto DAergic neurons, which was enhanced by 50% to
favor the activation model.</p><p>As described in Graupner et al.,<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> the
action of preterminal &#x003b1;7 NNRs was to enhance glutamate release.
Because &#x003b1;7 NNRs may evoke glutamate release in an impulse-independent
manner<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> and because we are faced in this
anesthetized in vivo condition with asynchronous inputs from probably
tens of afferents, the steady-state terms for spike-evoked and &#x003b1;7-evoked
glutamate release were simply added. Hence, the glutamatergic receptor
currents were assumed to be proportional to the amount of glutamate
released, with a negative sign for the mGluRs.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> Because glutamatergic and dopaminergic terminals often
make apposed synapses onto the same medium spiny neuron in nucleus
accumbens, diffusion at locations 3 (Figure <xref rid="fig2" ref-type="fig">2</xref>A) and 5 (Figure <xref rid="fig3" ref-type="fig">3</xref>A) of the circuit was assumed
to be much faster than the measured responses. Our mean-field approach
further implicitly assumed that at the concentrations of spilled-over
glutamate, NMDA receptors do not substantially desensitize.</p></sec><sec id="sec4.2.3"><title>Extracellular
Dopamine Concentration</title><p>The final outcome
of the model was obtained by mapping the mean spike rate of the dopamine
neurons onto the variable representing the extracellular dopamine
concentration. Although dopamine is particularly released during phasic
firing,<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> recent cyclic voltammetry in
anesthetized mice showed a fairly linear increase with stimulation
frequency.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> We further assumed a steady-state
dopamine concentration of about 50 nM, except in Figure <xref rid="fig6" ref-type="fig">6</xref> where baseline dopamine concentration was 337 nM. These assumptions
allowed us to calculate the dopamine concentration, <italic>C</italic>, using the following equation:<disp-formula id="ueq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00126t_m002" position="anchor"/></disp-formula></p><p>The first term on the right-hand side
adds dopamine in proportion to the enhancement in spike rate, <italic>r</italic>, relative to the steady-state rate, <italic>r</italic><sub>ss</sub> (measured before any drug administration). Dopamine
leaks away (second term) and is resorbed by an uptake process with
Michaelis&#x02013;Menten kinetics of maximum rate, <italic>V</italic><sub>m</sub>, and affinity, <italic>K</italic><sub>m</sub> (last
term). We set <italic>V</italic><sub>m</sub> to 1.3 &#x003bc;M s<sup>&#x02013;1</sup>, <italic>K</italic><sub>m</sub> to 0.2 &#x003bc;M,
and &#x003c4; to 200 ms.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> By setting <italic>C</italic><sub>b</sub> (the basal dopamine concentration in the absence
of input or uptake) to 100 nM (500 nM for Figure <xref rid="fig6" ref-type="fig">6</xref>), we obtained a steady-state concentration of about 50 nM.</p></sec></sec></sec></body><back><notes id="notes-2" notes-type="si"><title>Supporting Information Available</title><p>Detailed comparative responses
of the two models, a consideration of a third mechanism (coagonism),
and a discussion of the generalization of our findings to prefrontal
cortex. This material is available free of charge via the Internet
at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn500126t_si_001.pdf"><caption><p>cn500126t_si_001.pdf</p></caption></media></supplementary-material></sec><notes id="notes-1"><title>Author Contributions</title><p>V.P.G., E.B.,
M.B., and B.G. designed and supervised the study. R.M. performed the
simulations. V.P.G., V.G., and E.B. performed the experiments. R.M.,
V.P.G., E.B., M.B., and B.G. wrote the manuscript.</p></notes><notes id="fs1" notes-type="funding-statement"><p>This work was part
of the Collaborative research on NNR/DA integrative pharmacology (PCR-INP10/01),
awarded to M.B. and B.G. and was partly supported by IdEx ANR-11-0001-02
PSL* and LabEx ANR-10-LABX-0087 (France). Experimental work was supported
by grants from the National Institutes of Health (AA020564) and the
Tab Williams Family Endowment Fund to E.B. B.G. acknowledges support
from the Basic Research Program of the National Research University
Higher School of Economics (Russia).</p></notes><notes id="NOTES-d3521e1475-autogenerated" notes-type="conflict-of-interest"><p>The authors declare
the
following competing financial interest(s): M.B. is an employee and
stockholder of Targacept Inc., a biopharmaceutical company involved
in research and development of drugs targeting the neuronal nicotinic
receptors.</p></notes><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>ACh</term><def><p>acetylcholine</p></def></def-item><def-item><term>DA</term><def><p>dopamine</p></def></def-item><def-item><term>FSCV</term><def><p>fact-scan cyclic voltammetry</p></def></def-item><def-item><term>GABA</term><def><p>&#x003b3;-amino butyric
acid</p></def></def-item><def-item><term>MLA</term><def><p>methyllycaconitine
citrate</p></def></def-item><def-item><term>NNR</term><def><p>neuronal
nicotinic receptor</p></def></def-item><def-item><term>PAM</term><def><p>positive allosteric modulator</p></def></def-item><def-item><term>PNU-120596</term><def><p>1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea</p></def></def-item><def-item><term>TC-7020</term><def><p>(2<italic>S</italic>,3<italic>R</italic>)-5-methyl-<italic>N</italic>-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]thiophene-2-carboxamide</p></def></def-item><def-item><term>VTA</term><def><p>ventral tegmental
area</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Geerts</surname><given-names>H.</given-names></name> (<year>2012</year>) <article-title>&#x003b1;7 Nicotinic
receptor modulators for cognitive deficits in schizophrenia and Alzheimer&#x02019;s
disease</article-title>. <source>Expert Opin. Invest. Drugs</source>
<volume>21</volume>, <fpage>59</fpage>&#x02013;<lpage>65</lpage>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Kucinski</surname><given-names>A. J.</given-names></name>; <name><surname>Stachowiak</surname><given-names>M. K.</given-names></name>; <name><surname>Wersinger</surname><given-names>S. R.</given-names></name>; <name><surname>Lippiello</surname><given-names>P. M.</given-names></name>; <name><surname>Bencherif</surname><given-names>M.</given-names></name> (<year>2011</year>) <article-title>Alpha7 neuronal
nicotinic receptors as targets for
novel therapies to treat multiple domains of schizophrenia</article-title>. <source>Curr. Pharm. Biotechnol.</source>
<volume>12</volume>, <fpage>437</fpage>&#x02013;<lpage>448</lpage>.<pub-id pub-id-type="pmid">21133847</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Wallace</surname><given-names>T. L.</given-names></name>; <name><surname>Bertrand</surname><given-names>D.</given-names></name> (<year>2013</year>) <article-title>Alpha7 neuronal nicotinic receptors as a drug target
in schizophrenia</article-title>. <source>Expert Opin. Ther. Targets</source>
<volume>17</volume>, <fpage>139</fpage>&#x02013;<lpage>155</lpage>.<pub-id pub-id-type="pmid">23231385</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Quik</surname><given-names>M.</given-names></name>; <name><surname>Wonnacott</surname><given-names>S.</given-names></name> (<year>2011</year>) <article-title>&#x003b1;6&#x003b2;2*
and &#x003b1;4&#x003b2;2* Nicotinic acetylcholine
receptors as drug targets for Parkinson&#x02019;s disease</article-title>. <source>Pharmacol. Rev.</source>
<volume>63</volume>, <fpage>938</fpage>&#x02013;<lpage>966</lpage>.<pub-id pub-id-type="pmid">21969327</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Zhou</surname><given-names>F. M.</given-names></name>; <name><surname>Liang</surname><given-names>Y.</given-names></name>; <name><surname>Dani</surname><given-names>J. A.</given-names></name> (<year>2001</year>) <article-title>Endogenous nicotinic cholinergic
activity regulates dopamine release in the striatum</article-title>. <source>Nat. Neurosci.</source>
<volume>4</volume>, <fpage>1224</fpage>&#x02013;<lpage>1229</lpage>.<pub-id pub-id-type="pmid">11713470</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Brazell</surname><given-names>M. P.</given-names></name>; <name><surname>Mitchell</surname><given-names>S. N.</given-names></name>; <name><surname>Joseph</surname><given-names>M. H.</given-names></name>; <name><surname>Gray</surname><given-names>J. A.</given-names></name> (<year>1990</year>) <article-title>Acute administration
of nicotine increases the <italic>in vivo</italic> extracellular levels
of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially
in the nucleus accumbens of the rat: comparison with caudate-putamen</article-title>. <source>Neuropharmacology</source>
<volume>29</volume>, <fpage>1177</fpage>&#x02013;<lpage>1185</lpage>.<pub-id pub-id-type="pmid">2293060</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Cheer</surname><given-names>J. F.</given-names></name>; <name><surname>Wassum</surname><given-names>K. M.</given-names></name>; <name><surname>Sombers</surname><given-names>L. A.</given-names></name>; <name><surname>Heien</surname><given-names>M. L.</given-names></name>; <name><surname>Ariansen</surname><given-names>J. L.</given-names></name>; <name><surname>Aragona</surname><given-names>B. J.</given-names></name>; <name><surname>Phillips</surname><given-names>P. E.</given-names></name>; <name><surname>Wightman</surname><given-names>R. M.</given-names></name> (<year>2007</year>) <article-title>Phasic dopamine
release evoked by abused substances requires cannabinoid receptor
activation</article-title>. <source>J. Neurosci.</source>
<volume>27</volume>, <fpage>791</fpage>&#x02013;<lpage>795</lpage>.<pub-id pub-id-type="pmid">17251418</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Mameli-Engvall</surname><given-names>M.</given-names></name>; <name><surname>Evrard</surname><given-names>A.</given-names></name>; <name><surname>Pons</surname><given-names>S.</given-names></name>; <name><surname>Maskos</surname><given-names>U.</given-names></name>; <name><surname>Svensson</surname><given-names>T. H.</given-names></name>; <name><surname>Changeux</surname><given-names>J. P.</given-names></name>; <name><surname>Faure</surname><given-names>P.</given-names></name> (<year>2006</year>) <article-title>Hierarchical control
of dopamine
neuron-firing patterns by nicotinic receptors</article-title>. <source>Neuron</source>
<volume>50</volume>, <fpage>911</fpage>&#x02013;<lpage>921</lpage>.<pub-id pub-id-type="pmid">16772172</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Schilstr&#x000f6;m</surname><given-names>B.</given-names></name>; <name><surname>Svensson</surname><given-names>H. M.</given-names></name>; <name><surname>Svensson</surname><given-names>T. H.</given-names></name>; <name><surname>Nomikos</surname><given-names>G. G.</given-names></name> (<year>1998</year>) <article-title>Nicotine and food
induced dopamine release in the nucleus accumbens of the rat: putative
role of &#x003b1;7 nicotinic receptors in the ventral tegmental area</article-title>. <source>Neuroscience</source>
<volume>85</volume>, <fpage>1005</fpage>&#x02013;<lpage>1009</lpage>.<pub-id pub-id-type="pmid">9681941</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Good</surname><given-names>C. H.</given-names></name>; <name><surname>Lupica</surname><given-names>C. R.</given-names></name> (<year>2009</year>) <article-title>Properties of distinct ventral tegmental area synapses
activated via pedunculopontine or ventral tegmental area stimulation <italic>in vitro</italic></article-title>. <source>J. Physiol.</source>
<volume>587</volume>, <fpage>1233</fpage>&#x02013;<lpage>1247</lpage>.<pub-id pub-id-type="pmid">19188251</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Taylor</surname><given-names>D. H.</given-names></name>; <name><surname>Burman</surname><given-names>P. N.</given-names></name>; <name><surname>Hansen</surname><given-names>M. D.</given-names></name>; <name><surname>Wlcox</surname><given-names>R. S.</given-names></name>; <name><surname>Larsen</surname><given-names>B. R.</given-names></name>; <name><surname>Blanchard</surname><given-names>J. K.</given-names></name>; <name><surname>Merrill</surname><given-names>C. B.</given-names></name>; <name><surname>Edwards</surname><given-names>J. G.</given-names></name>; <name><surname>Sudweeks</surname><given-names>S. N.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Arias</surname><given-names>H. R.</given-names></name>; <name><surname>Steffensen</surname><given-names>S. C.</given-names></name> (<year>2013</year>) <article-title>Nicotine enhances the excitability
of Gaba neurons in the ventral tegmental area via activation of alpha
7 nicotinic receptors on glutamate terminals</article-title>. <source>Biochem. Pharmacol.</source>
<volume>S1</volume>, <elocation-id>007</elocation-id>.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Tolu</surname><given-names>S.</given-names></name>; <name><surname>Eddine</surname><given-names>R.</given-names></name>; <name><surname>Marti</surname><given-names>F.</given-names></name>; <name><surname>David</surname><given-names>V.</given-names></name>; <name><surname>Graupner</surname><given-names>M.</given-names></name>; <name><surname>Pons</surname><given-names>S.</given-names></name>; <name><surname>Baudonnat</surname><given-names>M.</given-names></name>; <name><surname>Husson</surname><given-names>M.</given-names></name>; <name><surname>Besson</surname><given-names>M.</given-names></name>; <name><surname>Reperant</surname><given-names>C.</given-names></name>; <name><surname>Zemdegs</surname><given-names>J.</given-names></name>; <name><surname>Pages</surname><given-names>C.</given-names></name>; <name><surname>Hay</surname><given-names>Y. A.</given-names></name>; <name><surname>Lambolez</surname><given-names>B.</given-names></name>; <name><surname>Caboche</surname><given-names>J.</given-names></name>; <name><surname>Gutkin</surname><given-names>B.</given-names></name>; <name><surname>Gardier</surname><given-names>A. M.</given-names></name>; <name><surname>Changeux</surname><given-names>J. P.</given-names></name>; <name><surname>Faure</surname><given-names>P.</given-names></name>; <name><surname>Maskos</surname><given-names>U.</given-names></name> (<year>2013</year>) <article-title>Co-activation of VTA
DA and GABA neurons mediates nicotine reinforcement</article-title>. <source>Mol. Psychiatry</source>
<volume>18</volume>, <fpage>382</fpage>&#x02013;<lpage>393</lpage>.<pub-id pub-id-type="pmid">22751493</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Forster</surname><given-names>G. L.</given-names></name>; <name><surname>Blaha</surname><given-names>C. D.</given-names></name> (<year>2000</year>) <article-title>Laterodorsal tegmental stimulation elicits dopamine
efflux in the rat nucleus accumbens by activation of acetylcholine
and glutamate receptors in the ventral tegmental area</article-title>. <source>Eur. J. Neurosci.</source>
<volume>12</volume>, <fpage>3596</fpage>&#x02013;<lpage>3604</lpage>.<pub-id pub-id-type="pmid">11029630</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Schilstr&#x000f6;m</surname><given-names>B.</given-names></name>; <name><surname>Fagerquist</surname><given-names>M. V.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Hertel</surname><given-names>P.</given-names></name>; <name><surname>Panagis</surname><given-names>G.</given-names></name>; <name><surname>Nomikos</surname><given-names>G. G.</given-names></name>; <name><surname>Svensson</surname><given-names>T. H.</given-names></name> (<year>2000</year>) <article-title>Putative role of presynaptic alpha7*
nicotinic receptors in nicotine stimulated increases of extracellular
levels of glutamate and aspartate in the ventral tegmental area</article-title>. <source>Synapse</source>
<volume>38</volume>, <fpage>375</fpage>&#x02013;<lpage>383</lpage>.<pub-id pub-id-type="pmid">11044884</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Cachope</surname><given-names>R.</given-names></name>; <name><surname>Mateo</surname><given-names>Y.</given-names></name>; <name><surname>Mathur</surname><given-names>B. N.</given-names></name>; <name><surname>Irving</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>H. L.</given-names></name>; <name><surname>Morales</surname><given-names>M.</given-names></name>; <name><surname>Lovinger</surname><given-names>D. M.</given-names></name>; <name><surname>Cheer</surname><given-names>J. F.</given-names></name> (<year>2012</year>) <article-title>Selective activation
of cholinergic interneurons enhances accumbal phasic dopamine release:
Setting the tone for reward processing</article-title>. <source>Cell
Rep.</source>
<volume>2</volume>, <fpage>33</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">22840394</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Threlfell</surname><given-names>S.</given-names></name>; <name><surname>Lalic</surname><given-names>T.</given-names></name>; <name><surname>Platt</surname><given-names>N. J.</given-names></name>; <name><surname>Jennings</surname><given-names>K. A.</given-names></name>; <name><surname>Deisseroth</surname><given-names>K.</given-names></name>; <name><surname>Cragg</surname><given-names>S. J.</given-names></name> (<year>2012</year>) <article-title>Striatal dopamine
release is triggered by synchronized
activity in cholinergic interneurons</article-title>. <source>Neuron</source>
<volume>75</volume>, <fpage>58</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">22794260</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Koranda</surname><given-names>J. L.</given-names></name>; <name><surname>Cone</surname><given-names>J. J.</given-names></name>; <name><surname>McGehee</surname><given-names>D. S.</given-names></name>; <name><surname>Roitman</surname><given-names>M. F.</given-names></name>; <name><surname>Beeler</surname><given-names>J. A.</given-names></name>; <name><surname>Zhuang</surname><given-names>X.</given-names></name> (<year>2014</year>) <article-title>Nicotinic receptors
regulate the dynamic range of dopamine
release in vivo</article-title>. <source>J. Neurophysiol.</source>
<volume>111</volume>, <fpage>103</fpage>&#x02013;<lpage>111</lpage>.<pub-id pub-id-type="pmid">24089398</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Grilli</surname><given-names>M.</given-names></name>; <name><surname>Summa</surname><given-names>M.</given-names></name>; <name><surname>Salamone</surname><given-names>A.</given-names></name>; <name><surname>Olivero</surname><given-names>G.</given-names></name>; <name><surname>Zappettini</surname><given-names>S.</given-names></name>; <name><surname>Di Prisco</surname><given-names>S.</given-names></name>; <name><surname>Feligioni</surname><given-names>M.</given-names></name>; <name><surname>Usai</surname><given-names>C.</given-names></name>; <name><surname>Pittaluga</surname><given-names>A.</given-names></name>; <name><surname>Marchi</surname><given-names>M.</given-names></name> (<year>2012</year>) <article-title><italic>In vitro</italic> exposure to nicotine induces
endocytosis of presynaptic AMPA receptors modulating dopamine release
in rat nucleus accumbens nerve terminals</article-title>. <source>Neuropharmacology</source>
<volume>63</volume>, <fpage>916</fpage>&#x02013;<lpage>926</lpage>.<pub-id pub-id-type="pmid">22771975</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Kaiser</surname><given-names>S.</given-names></name>; <name><surname>Wonnacott</surname><given-names>S.</given-names></name> (<year>2000</year>) <article-title>&#x003b1;-Bungarotoxin-sensitive
nicotinic receptors
indirectly modulate [<sup>3</sup>H]dopamine release in rat striatal
slices via glutamate release</article-title>. <source>Mol. Pharmacol.</source>
<volume>58</volume>, <fpage>312</fpage>&#x02013;<lpage>318</lpage>.<pub-id pub-id-type="pmid">10908298</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Marrero</surname><given-names>M. B.</given-names></name>; <name><surname>Lucas</surname><given-names>R.</given-names></name>; <name><surname>Salet</surname><given-names>C.</given-names></name>; <name><surname>Hauser</surname><given-names>T. A.</given-names></name>; <name><surname>Mazurov</surname><given-names>A.</given-names></name>; <name><surname>Lippiello</surname><given-names>P. M.</given-names></name>; <name><surname>Bencherif</surname><given-names>M.</given-names></name> (<year>2010</year>) <article-title>An &#x003b1;7 nicotinic acetylcholine
receptor-selective agonist reduces weight gain and metabolic changes
in a mouse model of diabetes</article-title>. <source>J. Pharmacol.
Exp. Ther.</source>
<volume>332</volume>, <fpage>173</fpage>&#x02013;<lpage>180</lpage>.<pub-id pub-id-type="pmid">19786623</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Narla</surname><given-names>S.</given-names></name>; <name><surname>Klejbor</surname><given-names>I.</given-names></name>; <name><surname>Birkaya</surname><given-names>B.</given-names></name>; <name><surname>Lee</surname><given-names>Y. W.</given-names></name>; <name><surname>Morys</surname><given-names>J.</given-names></name>; <name><surname>Stachowiak</surname><given-names>E. K.</given-names></name>; <name><surname>Terranova</surname><given-names>C.</given-names></name>; <name><surname>Bencherif</surname><given-names>M.</given-names></name>; <name><surname>Stachowiak</surname><given-names>M. K.</given-names></name> (<year>2013</year>) <article-title>&#x003b1;7
Nicotinic receptor agonist reactivates neurogenesis
in adult brain</article-title>. <source>Biochem. Pharmacol.</source>
<volume>86</volume>, <fpage>1099</fpage>&#x02013;<lpage>1104</lpage>.<pub-id pub-id-type="pmid">23933384</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Kucinski</surname><given-names>A.</given-names></name>; <name><surname>Syposs</surname><given-names>C.</given-names></name>; <name><surname>Wersinger</surname><given-names>S.</given-names></name>; <name><surname>Bencherif</surname><given-names>M.</given-names></name>; <name><surname>Stachowiak</surname><given-names>M. K.</given-names></name>; <name><surname>Stachowiak</surname><given-names>E. K.</given-names></name> (<year>2012</year>) <article-title>&#x003b1;7
Neuronal nicotinic receptor
agonist (TC-7020) reverses increased striatal dopamine release during
acoustic PPI testing in a transgenic mouse model of schizophrenia</article-title>. <source>Schizophr. Res.</source>
<volume>136</volume>, <fpage>82</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">22285656</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Garz&#x000f3;n</surname><given-names>M.</given-names></name>; <name><surname>Duffy</surname><given-names>A. M.</given-names></name>; <name><surname>Chan</surname><given-names>J.</given-names></name>; <name><surname>Lynch</surname><given-names>M. K.</given-names></name>; <name><surname>Mackie</surname><given-names>K.</given-names></name>; <name><surname>Pickel</surname><given-names>V. M.</given-names></name> (<year>2013</year>) <article-title>Dopamine D2 and acetylcholine &#x003b1;7 nicotinic receptors
have subcellular distributions favoring mediation of convergent signaling
in the mouse ventral tegmental area</article-title>. <source>Neuroscience</source>
<volume>252</volume>, <fpage>126</fpage>&#x02013;<lpage>143</lpage>.<pub-id pub-id-type="pmid">23954803</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Jones</surname><given-names>I. W.</given-names></name>; <name><surname>Wonnacott</surname><given-names>S.</given-names></name> (<year>2004</year>) <article-title>Precise localization
of &#x003b1;7 nicotinic acetylcholine
receptors on glutamatergic axon terminals in the rat ventral tegmental
area</article-title>. <source>J. Neurosci.</source>
<volume>24</volume>, <fpage>11244</fpage>&#x02013;<lpage>11252</lpage>.<pub-id pub-id-type="pmid">15601930</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Livingstone</surname><given-names>P. D.</given-names></name>; <name><surname>Dickinson</surname><given-names>J. A.</given-names></name>; <name><surname>Srinivasan</surname><given-names>J.</given-names></name>; <name><surname>Kew</surname><given-names>J. N.</given-names></name>; <name><surname>Wonnacott</surname><given-names>S.</given-names></name> (<year>2010</year>) <article-title>Glutamate-dopamine
crosstalk in the rat prefrontal cortex is modulated by alpha7 nicotinic
receptors and potentiated by PNU-120596</article-title>. <source>J.
Mol. Neurosci.</source>
<volume>40</volume>, <fpage>172</fpage>&#x02013;<lpage>176</lpage>.<pub-id pub-id-type="pmid">19688191</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Paspalas</surname><given-names>C. D.</given-names></name>; <name><surname>Jin</surname><given-names>L. E.</given-names></name>; <name><surname>Picciotto</surname><given-names>M. R.</given-names></name>; <name><surname>Arnsten</surname><given-names>A. F.</given-names></name>; <name><surname>Wang</surname><given-names>M.</given-names></name> (<year>2013</year>) <article-title>Nicotinic &#x003b1;7 receptors enhance
NMDA cognitive circuits in dorsolateral prefrontal cortex</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>110</volume>, <fpage>12078</fpage>&#x02013;<lpage>12083</lpage>.<pub-id pub-id-type="pmid">23818597</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Jin</surname><given-names>Y.</given-names></name>; <name><surname>Yang</surname><given-names>K.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name> (<year>2011</year>) <article-title>Exposure of nicotine
to ventral tegmental area slices induces glutamatergic synaptic plasticity
on dopamine neurons</article-title>. <source>Synapse</source>
<volume>65</volume>, <fpage>332</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">20730803</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Melis</surname><given-names>M.</given-names></name>; <name><surname>Scheggi</surname><given-names>S.</given-names></name>; <name><surname>Carta</surname><given-names>G.</given-names></name>; <name><surname>Madeddu</surname><given-names>C.</given-names></name>; <name><surname>Lecca</surname><given-names>S.</given-names></name>; <name><surname>Luchicchi</surname><given-names>A.</given-names></name>; <name><surname>Cadeddu</surname><given-names>F.</given-names></name>; <name><surname>Frau</surname><given-names>R.</given-names></name>; <name><surname>Fattore</surname><given-names>L.</given-names></name>; <name><surname>Fadda</surname><given-names>P.</given-names></name>; <name><surname>Ennas</surname><given-names>M. G.</given-names></name>; <name><surname>Castelli</surname><given-names>M. P.</given-names></name>; <name><surname>Fratta</surname><given-names>W.</given-names></name>; <name><surname>Schilstrom</surname><given-names>B.</given-names></name>; <name><surname>Banni</surname><given-names>S.</given-names></name>; <name><surname>De Montis</surname><given-names>M. G.</given-names></name>; <name><surname>Pistis</surname><given-names>M.</given-names></name> (<year>2013</year>) <article-title>PPAR&#x003b1; regulates cholinergic-driven activity of
midbrain dopamine neurons via a novel mechanism involving &#x003b1;7
nicotinic acetylcholine receptors</article-title>. <source>J. Neurosci.</source>
<volume>33</volume>, <fpage>6203</fpage>&#x02013;<lpage>6211</lpage>.<pub-id pub-id-type="pmid">23554501</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Hurst</surname><given-names>R. S.</given-names></name>; <name><surname>Haj&#x000f3;s</surname><given-names>M.</given-names></name>; <name><surname>Raggenbass</surname><given-names>M.</given-names></name>; <name><surname>Wall</surname><given-names>T. M.</given-names></name>; <name><surname>Higdon</surname><given-names>N. R.</given-names></name>; <name><surname>Lawson</surname><given-names>J. A.</given-names></name>; <name><surname>Rutherford-Root</surname><given-names>K. L.</given-names></name>; <name><surname>Berkenpas</surname><given-names>M. B.</given-names></name>; <name><surname>Hoffmann</surname><given-names>W. E.</given-names></name>; <name><surname>Piotrowski</surname><given-names>D. W.</given-names></name>; <name><surname>Groppi</surname><given-names>V. E.</given-names></name>; <name><surname>Allaman</surname><given-names>G.</given-names></name>; <name><surname>Ogier</surname><given-names>R.</given-names></name>; <name><surname>Bertrand</surname><given-names>S.</given-names></name>; <name><surname>Bertrand</surname><given-names>D.</given-names></name>; <name><surname>Arneric</surname><given-names>S. P.</given-names></name> (<year>2005</year>) <article-title>A novel
positive allosteric modulator of the &#x003b1;7 neuronal nicotinic acetylcholine
receptor: <italic>in vitro</italic> and <italic>in vivo</italic> characterization</article-title>. <source>J. Neurosci.</source>
<volume>25</volume>, <fpage>4396</fpage>&#x02013;<lpage>4405</lpage>.<pub-id pub-id-type="pmid">15858066</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Schilstr&#x000f6;m</surname><given-names>B.</given-names></name>; <name><surname>Rawal</surname><given-names>N.</given-names></name>; <name><surname>Mameli-Engvall</surname><given-names>M.</given-names></name>; <name><surname>Nomikos</surname><given-names>G. G.</given-names></name>; <name><surname>Svensson</surname><given-names>T. H.</given-names></name> (<year>2003</year>) <article-title>Dual effects
of nicotine on dopamine neurons mediated by different nicotinic receptor
subtypes</article-title>. <source>Int. J. Neuropsychopharmacol.</source>
<volume>6</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">12899731</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>George</surname><given-names>A. A.</given-names></name>; <name><surname>Schroeder</surname><given-names>K. M.</given-names></name>; <name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Marxer-Miller</surname><given-names>S.</given-names></name>; <name><surname>Lucero</surname><given-names>L.</given-names></name>; <name><surname>Lukas</surname><given-names>R. J.</given-names></name> (<year>2004</year>) <article-title>Electrophysiological,
pharmacological,
and molecular evidence for &#x003b1;7-nicotinic acetylcholine receptors
in rat midbrain dopamine neurons</article-title>. <source>J. Pharmacol.
Exp. Ther.</source>
<volume>311</volume>, <fpage>80</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">15178698</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Klink</surname><given-names>R.</given-names></name>; <name><surname>de Kerchove d&#x02019;Exaerde</surname><given-names>A.</given-names></name>; <name><surname>Zoli</surname><given-names>M.</given-names></name>; <name><surname>Changeux</surname><given-names>J. P.</given-names></name> (<year>2001</year>) <article-title>Molecular
and physiological diversity of nicotinic acetylcholine receptors in
the midbrain dopaminergic nuclei</article-title>. <source>J. Neurosci.</source>
<volume>21</volume>, <fpage>1452</fpage>&#x02013;<lpage>1463</lpage>.<pub-id pub-id-type="pmid">11222635</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Yang</surname><given-names>K.</given-names></name>; <name><surname>Hu</surname><given-names>J.</given-names></name>; <name><surname>Lucero</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Zheng</surname><given-names>C.</given-names></name>; <name><surname>Zhen</surname><given-names>X.</given-names></name>; <name><surname>Jin</surname><given-names>G.</given-names></name>; <name><surname>Lukas</surname><given-names>R. J.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name> (<year>2009</year>) <article-title>Distinctive nicotinic acetylcholine
receptor functional phenotypes of rat ventral tegmental area dopaminergic
neurons</article-title>. <source>J. Physiol.</source>
<volume>587</volume>, <fpage>345</fpage>&#x02013;<lpage>361</lpage>.<pub-id pub-id-type="pmid">19047205</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Grady</surname><given-names>S. R.</given-names></name>; <name><surname>Salminen</surname><given-names>O.</given-names></name>; <name><surname>Laverty</surname><given-names>D. C.</given-names></name>; <name><surname>Whiteaker</surname><given-names>P.</given-names></name>; <name><surname>McIntosh</surname><given-names>J. M.</given-names></name>; <name><surname>Collins</surname><given-names>A. C.</given-names></name>; <name><surname>Marks</surname><given-names>M. J.</given-names></name> (<year>2007</year>) <article-title>The subtypes of
nicotinic acetylcholine receptors on dopaminergic terminals of mouse
striatum</article-title>. <source>Biochem. Pharmacol.</source>
<volume>74</volume>, <fpage>1235</fpage>&#x02013;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">17825262</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Livingstone</surname><given-names>P. D.</given-names></name>; <name><surname>Wonnacott</surname><given-names>S.</given-names></name> (<year>2009</year>) <article-title>Nicotinic
acetylcholine receptors and the ascending
dopamine pathways</article-title>. <source>Biochem. Pharmacol.</source>
<volume>78</volume>, <fpage>744</fpage>&#x02013;<lpage>755</lpage>.<pub-id pub-id-type="pmid">19523928</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Sulzer</surname><given-names>D.</given-names></name> (<year>2003</year>) <article-title>Glutamate spillover
in the striatum depresses dopaminergic
transmission by activating group I metabotropic glutamate receptors</article-title>. <source>J. Neurosci.</source>
<volume>23</volume>, <fpage>10585</fpage>&#x02013;<lpage>10592</lpage>.<pub-id pub-id-type="pmid">14627643</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Papke</surname><given-names>R. L.</given-names></name>; <name><surname>Kem</surname><given-names>W. R.</given-names></name>; <name><surname>Soti</surname><given-names>F.</given-names></name>; <name><surname>Lopez-Hernandez</surname><given-names>G. Y.</given-names></name>; <name><surname>Horenstein</surname><given-names>N. A.</given-names></name> (<year>2009</year>) <article-title>Activation and desensitization of nicotinic &#x003b1;7-type
acetylcholine receptors by benzylidene anabaseines and nicotine</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>329</volume>, <fpage>791</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">19223664</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Kalappa</surname><given-names>B. I.</given-names></name>; <name><surname>Uteshev</surname><given-names>V. V.</given-names></name> (<year>2013</year>) <article-title>The dual effect of PNU-120596 on &#x003b1;7 nicotinic
acetylcholine receptor channels</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>718</volume>, <fpage>226</fpage>&#x02013;<lpage>234</lpage>.<pub-id pub-id-type="pmid">24036349</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Hu</surname><given-names>G.</given-names></name>; <name><surname>Duffy</surname><given-names>P.</given-names></name>; <name><surname>Swanson</surname><given-names>C.</given-names></name>; <name><surname>Ghasemzadeh</surname><given-names>M. B.</given-names></name>; <name><surname>Kalivas</surname><given-names>P. W.</given-names></name> (<year>1999</year>) <article-title>The regulation of dopamine transmission
by metabotropic
glutamate receptors</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>289</volume>, <fpage>412</fpage>&#x02013;<lpage>416</lpage>.<pub-id pub-id-type="pmid">10087032</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>van
Zessen</surname><given-names>R.</given-names></name>; <name><surname>Phillips</surname><given-names>J. L.</given-names></name>; <name><surname>Budygin</surname><given-names>E. A.</given-names></name>; <name><surname>Stuber</surname><given-names>G. D.</given-names></name> (<year>2012</year>) <article-title>Activation
of VTA GABA neurons disrupts reward consumption</article-title>. <source>Neuron</source>
<volume>73</volume>, <fpage>1184</fpage>&#x02013;<lpage>1194</lpage>.<pub-id pub-id-type="pmid">22445345</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Sherwood</surname><given-names>J. L.</given-names></name>; <name><surname>Miles</surname><given-names>C. P.</given-names></name>; <name><surname>Whiffin</surname><given-names>G.</given-names></name>; <name><surname>Lodge</surname><given-names>D.</given-names></name> (<year>2006</year>) <article-title>TC-2559 excites
dopaminergic neurones in the ventral tegmental area by stimulating
&#x003b1;4&#x003b2;2-like nicotinic acetylcholine receptors in anaesthetised
rats</article-title>. <source>Br. J. Pharmacol.</source>
<volume>147</volume>, <fpage>379</fpage>&#x02013;<lpage>390</lpage>.<pub-id pub-id-type="pmid">16402043</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Glowinski</surname><given-names>J.</given-names></name>; <name><surname>Cheramy</surname><given-names>A.</given-names></name>; <name><surname>Romo</surname><given-names>R.</given-names></name>; <name><surname>Barbeito</surname><given-names>L.</given-names></name> (<year>1988</year>) <article-title>Presynaptic
regulation
of dopaminergic transmission in the striatum</article-title>. <source>Cell. Mol. Neurobiol.</source>
<volume>8</volume>, <fpage>7</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">2900072</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Cheramy</surname><given-names>A.</given-names></name>; <name><surname>Desce</surname><given-names>J. M.</given-names></name>; <name><surname>Godeheu</surname><given-names>G.</given-names></name>; <name><surname>Glowinski</surname><given-names>J.</given-names></name> (<year>1994</year>) <article-title>Presynaptic
control of dopamine synthesis and release by excitatory amino acids
in rat striatal synaptosomes</article-title>. <source>Neurochem. Int.</source>
<volume>25</volume>, <fpage>145</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">7994195</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Marchi</surname><given-names>M.</given-names></name>; <name><surname>Risso</surname><given-names>F.</given-names></name>; <name><surname>Viola</surname><given-names>C.</given-names></name>; <name><surname>Cavazzani</surname><given-names>P.</given-names></name>; <name><surname>Raiteri</surname><given-names>M.</given-names></name> (<year>2002</year>) <article-title>Direct evidence that release-stimulating
&#x003b1;7*
nicotinic cholinergic receptors are localized on human and rat brain
glutamatergic axon terminals</article-title>. <source>J. Neurochem.</source>
<volume>80</volume>, <fpage>1071</fpage>&#x02013;<lpage>1078</lpage>.<pub-id pub-id-type="pmid">11953457</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Garcao</surname><given-names>P.</given-names></name>; <name><surname>Oliveira</surname><given-names>C. R.</given-names></name>; <name><surname>Cunha</surname><given-names>R. A.</given-names></name>; <name><surname>Agostinho</surname><given-names>P.</given-names></name> (<year>2014</year>) <article-title>Subsynaptic
localization of nicotinic acetylcholine receptor subunits: A comparative
study in the mouse and rat striatum</article-title>. <source>Neurosci.
Lett.</source>
<volume>566</volume>, <fpage>106</fpage>&#x02013;<lpage>110</lpage>.<pub-id pub-id-type="pmid">24607281</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Lenoir</surname><given-names>M.</given-names></name>; <name><surname>Kiyatkin</surname><given-names>E. A.</given-names></name> (<year>2013</year>) <article-title>Intravenous nicotine
injection induces rapid, experience-dependent
sensitization of glutamate release in the ventral tegmental area and
nucleus accumbens</article-title>. <source>J. Neurochem.</source>
<volume>127</volume>, <fpage>541</fpage>&#x02013;<lpage>551</lpage>.<pub-id pub-id-type="pmid">24032718</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Goldberg</surname><given-names>J. A.</given-names></name>; <name><surname>Reynolds</surname><given-names>J. N.</given-names></name> (<year>2011</year>) <article-title>Spontaneous firing
and evoked pauses in the tonically
active cholinergic interneurons of the striatum</article-title>. <source>Neuroscience</source>
<volume>198</volume>, <fpage>27</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">21925242</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="book" id="cit48"><person-group person-group-type="allauthors"><name><surname>Albuquerque</surname><given-names>E. X.</given-names></name>, <name><surname>Pereira</surname><given-names>E. F. R.</given-names></name>, and <name><surname>Alkondon</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>) <article-title>Tonic activation of &#x003b1;7 nicotinic acetylcholine
receptors (nAChRs) controls glutamatergic inputs to striatal and parietal
cortical neurons in guinea pig brain slices</article-title>, in <source>Society for Neuroscience Annual Meeting</source>, p <fpage>224.01</fpage>, <publisher-name>Society for Neuroscience</publisher-name>, <publisher-loc>San Diego, CA</publisher-loc>.</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Wu</surname><given-names>H. Q.</given-names></name>; <name><surname>Rassoulpour</surname><given-names>A.</given-names></name>; <name><surname>Schwarcz</surname><given-names>R.</given-names></name> (<year>2007</year>) <article-title>Kynurenic acid leads, dopamine follows:
A new case of volume transmission in the brain?</article-title>. <source>J. Neural Transm.</source>
<volume>114</volume>, <fpage>33</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">16932989</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Kulagina</surname><given-names>N. V.</given-names></name>; <name><surname>Zigmond</surname><given-names>M. J.</given-names></name>; <name><surname>Michael</surname><given-names>A. C.</given-names></name> (<year>2001</year>) <article-title>Glutamate regulates the spontaneous
and evoked release of dopamine in the rat striatum</article-title>. <source>Neuroscience</source>
<volume>102</volume>, <fpage>121</fpage>&#x02013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">11226675</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Moquin</surname><given-names>K. F.</given-names></name>; <name><surname>Michael</surname><given-names>A. C.</given-names></name> (<year>2010</year>) <article-title>Evidence for coupling between steady-state
and dynamic extracellular dopamine concentrations in the rat striatum</article-title>. <source>J. Neurochem.</source>
<volume>114</volume>, <fpage>150</fpage>&#x02013;<lpage>159</lpage>.<pub-id pub-id-type="pmid">20403079</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Besson</surname><given-names>M.</given-names></name>; <name><surname>David</surname><given-names>V.</given-names></name>; <name><surname>Baudonnat</surname><given-names>M.</given-names></name>; <name><surname>Cazala</surname><given-names>P.</given-names></name>; <name><surname>Guilloux</surname><given-names>J. P.</given-names></name>; <name><surname>Reperant</surname><given-names>C.</given-names></name>; <name><surname>Cloez-Tayarani</surname><given-names>I.</given-names></name>; <name><surname>Changeux</surname><given-names>J. P.</given-names></name>; <name><surname>Gardier</surname><given-names>A. M.</given-names></name>; <name><surname>Granon</surname><given-names>S.</given-names></name> (<year>2012</year>) <article-title>Alpha7-nicotinic receptors modulate nicotine-induced
reinforcement and extracellular dopamine outflow in the mesolimbic
system in mice</article-title>. <source>Psychopharmacology (Berlin,
Ger.)</source>
<volume>220</volume>, <fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Pearl</surname><given-names>S. M.</given-names></name>; <name><surname>Zigmond</surname><given-names>M. J.</given-names></name>; <name><surname>Michael</surname><given-names>A. C.</given-names></name> (<year>2000</year>) <article-title>Inhibitory glutamatergic
regulation of evoked dopamine release in striatum</article-title>. <source>Neuroscience</source>
<volume>96</volume>, <fpage>65</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">10683411</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="book" id="cit54"><person-group person-group-type="allauthors"><name><surname>Grinevich</surname><given-names>V. P.</given-names></name>, <name><surname>O&#x02019;Connor</surname><given-names>J. A.</given-names></name>, <name><surname>Bencherif</surname><given-names>M.</given-names></name>, and <name><surname>Budygin</surname><given-names>E. A.</given-names></name></person-group> (<year>2009</year>) <article-title>Effects of nicotine on real time dopamine dynamics
in rat nucleus accumbens: In vivo voltammetric study</article-title>, in <source>Society for Neuroscience Annual Meeting</source>, p <fpage>226.12</fpage>, <publisher-name>Society for Neuroscience</publisher-name>, <publisher-loc>Chicago</publisher-loc>.</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Campling</surname><given-names>B. G.</given-names></name>; <name><surname>Kuryatov</surname><given-names>A.</given-names></name>; <name><surname>Lindstrom</surname><given-names>J.</given-names></name> (<year>2013</year>) <article-title>Acute activation, desensitization
and smoldering activation of human acetylcholine receptors</article-title>. <source>PLoS One</source>
<volume>8</volume>, <elocation-id>e79653</elocation-id>.<pub-id pub-id-type="pmid">24244538</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Vinson</surname><given-names>P. N.</given-names></name>; <name><surname>Justice</surname><given-names>J. B.</given-names><suffix>Jr.</suffix></name> (<year>1997</year>) <article-title>Effect of neostigmine on concentration
and extraction fraction of acetylcholine using quantitative microdialysis</article-title>. <source>J. Neurosci. Methods</source>
<volume>73</volume>, <fpage>61</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">9130679</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Arroyo</surname><given-names>S.</given-names></name>; <name><surname>Bennett</surname><given-names>C.</given-names></name>; <name><surname>Hestrin</surname><given-names>S.</given-names></name> (<year>2014</year>) <article-title>Nicotinic modulation of cortical
circuits</article-title>. <source>Front. Neural Circuits</source>
<volume>8</volume>, <fpage>30</fpage>.<pub-id pub-id-type="pmid">24734005</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>Owesson-White</surname><given-names>C. A.</given-names></name>; <name><surname>Roitman</surname><given-names>M. F.</given-names></name>; <name><surname>Sombers</surname><given-names>L. A.</given-names></name>; <name><surname>Belle</surname><given-names>A. M.</given-names></name>; <name><surname>Keithley</surname><given-names>R. B.</given-names></name>; <name><surname>Peele</surname><given-names>J. L.</given-names></name>; <name><surname>Carelli</surname><given-names>R. M.</given-names></name>; <name><surname>Wightman</surname><given-names>R. M.</given-names></name> (<year>2012</year>) <article-title>Sources contributing
to the average extracellular concentration of dopamine in the nucleus
accumbens</article-title>. <source>J. Neurochem.</source>
<volume>121</volume>, <fpage>252</fpage>&#x02013;<lpage>262</lpage>.<pub-id pub-id-type="pmid">22296263</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Zuo</surname><given-names>P. L.</given-names></name>; <name><surname>Yao</surname><given-names>W.</given-names></name>; <name><surname>Sun</surname><given-names>L.</given-names></name>; <name><surname>Kuo</surname><given-names>S. T.</given-names></name>; <name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>S. R.</given-names></name>; <name><surname>Dou</surname><given-names>H. Q.</given-names></name>; <name><surname>Xu</surname><given-names>H. D.</given-names></name>; <name><surname>Zhang</surname><given-names>C. X.</given-names></name>; <name><surname>Kang</surname><given-names>X. J.</given-names></name>; <name><surname>Zhou</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name> (<year>2013</year>) <article-title>Impulse-dependent extracellular
resting
dopamine concentration in rat striatum in vivo</article-title>. <source>Neurochem. Int.</source>
<volume>62</volume>, <fpage>50</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">23159778</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Chen</surname><given-names>K. C.</given-names></name>; <name><surname>Budygin</surname><given-names>E. A.</given-names></name> (<year>2007</year>) <article-title>Extracting the basal extracellular dopamine concentrations
from the evoked responses: Re-analysis of the dopamine kinetics</article-title>. <source>J. Neurosci. Methods</source>
<volume>164</volume>, <fpage>27</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">17498808</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Shu</surname><given-names>Z.</given-names></name>; <name><surname>Taylor</surname><given-names>I. M.</given-names></name>; <name><surname>Michael</surname><given-names>A. C.</given-names></name> (<year>2013</year>) <article-title>The dopamine patchwork of the rat
nucleus accumbens core</article-title>. <source>Eur. J. Neurosci.</source>
<volume>38</volume>, <fpage>3221</fpage>&#x02013;<lpage>3229</lpage>.<pub-id pub-id-type="pmid">23937532</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>McLean</surname><given-names>S. L.</given-names></name>; <name><surname>Idris</surname><given-names>N. F.</given-names></name>; <name><surname>Grayson</surname><given-names>B.</given-names></name>; <name><surname>Gendle</surname><given-names>D. F.</given-names></name>; <name><surname>Mackie</surname><given-names>C.</given-names></name>; <name><surname>Lesage</surname><given-names>A. S.</given-names></name>; <name><surname>Pemberton</surname><given-names>D. J.</given-names></name>; <name><surname>Neill</surname><given-names>J. C.</given-names></name> (<year>2012</year>) <article-title>PNU-120596, a positive
allosteric modulator of &#x003b1;7 nicotinic acetylcholine receptors,
reverses a sub-chronic phencyclidine-induced cognitive deficit in
the attentional set-shifting task in female rats</article-title>. <source>J. Psychopharmacol.</source>
<volume>26</volume>, <fpage>1265</fpage>&#x02013;<lpage>1270</lpage>.<pub-id pub-id-type="pmid">22182741</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name><surname>Turek</surname><given-names>J. W.</given-names></name>; <name><surname>Kang</surname><given-names>C. H.</given-names></name>; <name><surname>Campbell</surname><given-names>J. E.</given-names></name>; <name><surname>Arneric</surname><given-names>S. P.</given-names></name>; <name><surname>Sullivan</surname><given-names>J. P.</given-names></name> (<year>1995</year>) <article-title>A sensitive
technique for the detection of the &#x003b1;7 neuronal nicotinic acetylcholine
receptor antagonist, methyllycaconitine, in rat plasma and brain</article-title>. <source>J. Neurosci. Methods</source>
<volume>61</volume>, <fpage>113</fpage>&#x02013;<lpage>118</lpage>.<pub-id pub-id-type="pmid">8618408</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Graupner</surname><given-names>M.</given-names></name>; <name><surname>Maex</surname><given-names>R.</given-names></name>; <name><surname>Gutkin</surname><given-names>B.</given-names></name> (<year>2013</year>) <article-title>Endogenous cholinergic inputs and
local circuit mechanisms govern the phasic mesolimbic dopamine response
to nicotine</article-title>. <source>PLoS Comput. Biol.</source>
<volume>9</volume>, <elocation-id>e1003183</elocation-id>.<pub-id pub-id-type="pmid">23966848</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name><surname>Grady</surname><given-names>S. R.</given-names></name>; <name><surname>Grun</surname><given-names>E. U.</given-names></name>; <name><surname>Marks</surname><given-names>M. J.</given-names></name>; <name><surname>Collins</surname><given-names>A. C.</given-names></name> (<year>1997</year>) <article-title>Pharmacological
comparison of transient and persistent [3H]dopamine release from mouse
striatal synaptosomes and response to chronic L-nicotine treatment</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>282</volume>, <fpage>32</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">9223537</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name><surname>Fenster</surname><given-names>C. P.</given-names></name>; <name><surname>Rains</surname><given-names>M. F.</given-names></name>; <name><surname>Noerager</surname><given-names>B.</given-names></name>; <name><surname>Quick</surname><given-names>M. W.</given-names></name>; <name><surname>Lester</surname><given-names>R. A.</given-names></name> (<year>1997</year>) <article-title>Influence
of subunit composition on desensitization of neuronal acetylcholine
receptors at low concentrations of nicotine</article-title>. <source>J. Neurosci.</source>
<volume>17</volume>, <fpage>5747</fpage>&#x02013;<lpage>5759</lpage>.<pub-id pub-id-type="pmid">9221773</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name><surname>Buisson</surname><given-names>B.</given-names></name>; <name><surname>Bertrand</surname><given-names>D.</given-names></name> (<year>2001</year>) <article-title>Chronic exposure to
nicotine upregulates the human
&#x003b1;4&#x003b2;2 nicotinic acetylcholine receptor function</article-title>. <source>J. Neurosci.</source>
<volume>21</volume>, <fpage>1819</fpage>&#x02013;<lpage>1829</lpage>.<pub-id pub-id-type="pmid">11245666</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Salminen</surname><given-names>O.</given-names></name>; <name><surname>Drapeau</surname><given-names>J. A.</given-names></name>; <name><surname>McIntosh</surname><given-names>J. M.</given-names></name>; <name><surname>Collins</surname><given-names>A. C.</given-names></name>; <name><surname>Marks</surname><given-names>M. J.</given-names></name>; <name><surname>Grady</surname><given-names>S. R.</given-names></name> (<year>2007</year>) <article-title>Pharmacology of &#x003b1;-conotoxin MII-sensitive subtypes
of nicotinic acetylcholine receptors isolated by breeding of null
mutant mice</article-title>. <source>Mol. Pharmacol.</source>
<volume>71</volume>, <fpage>1563</fpage>&#x02013;<lpage>1571</lpage>.<pub-id pub-id-type="pmid">17341654</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Engelman</surname><given-names>H. S.</given-names></name>; <name><surname>MacDermott</surname><given-names>A. B.</given-names></name> (<year>2004</year>) <article-title>Presynaptic ionotropic receptors
and control of transmitter
release</article-title>. <source>Nat. Rev. Neurosci.</source>
<volume>5</volume>, <fpage>135</fpage>&#x02013;<lpage>145</lpage>.<pub-id pub-id-type="pmid">14735116</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>Fiorillo</surname><given-names>C. D.</given-names></name>; <name><surname>Williams</surname><given-names>J. T.</given-names></name> (<year>1998</year>) <article-title>Glutamate mediates an inhibitory
postsynaptic potential
in dopamine neurons</article-title>. <source>Nature</source>
<volume>394</volume>, <fpage>78</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">9665131</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name><surname>Grace</surname><given-names>A. A.</given-names></name> (<year>1991</year>) <article-title>Phasic
versus tonic dopamine release and the modulation of dopamine system
responsivity: A hypothesis for the etiology of schizophrenia</article-title>. <source>Neuroscience</source>
<volume>41</volume>, <fpage>1</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">1676137</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name><surname>Papke</surname><given-names>R. L.</given-names></name>; <name><surname>Dwoskin</surname><given-names>L. P.</given-names></name>; <name><surname>Crooks</surname><given-names>P. A.</given-names></name> (<year>2007</year>) <article-title>The pharmacological activity of nicotine
and nornicotine on nAChRs subtypes: Relevance to nicotine dependence
and drug discovery</article-title>. <source>J. Neurochem.</source>
<volume>101</volume>, <fpage>160</fpage>&#x02013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">17241116</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name><surname>Grady</surname><given-names>S. R.</given-names></name>; <name><surname>Drenan</surname><given-names>R. M.</given-names></name>; <name><surname>Breining</surname><given-names>S. R.</given-names></name>; <name><surname>Yohannes</surname><given-names>D.</given-names></name>; <name><surname>Wageman</surname><given-names>C. R.</given-names></name>; <name><surname>Fedorov</surname><given-names>N. B.</given-names></name>; <name><surname>McKinney</surname><given-names>S.</given-names></name>; <name><surname>Whiteaker</surname><given-names>P.</given-names></name>; <name><surname>Bencherif</surname><given-names>M.</given-names></name>; <name><surname>Lester</surname><given-names>H. A.</given-names></name>; <name><surname>Marks</surname><given-names>M. J.</given-names></name> (<year>2010</year>) <article-title>Structural
differences
determine the relative selectivity of nicotinic compounds for native
&#x003b1;4&#x003b2;2*-, &#x003b1;6&#x003b2;2*-, &#x003b1;3&#x003b2;4*- and &#x003b1;7-nicotine
acetylcholine receptors</article-title>. <source>Neuropharmacology</source>
<volume>58</volume>, <fpage>1054</fpage>&#x02013;<lpage>1066</lpage>.<pub-id pub-id-type="pmid">20114055</pub-id></mixed-citation></ref></ref-list></back></article>